• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM

IMMUTEP LIMITED - News & Media

4.08% ! 23.5¢
Market Cap $344.9M  !
Healthcare Biotechnology
Add to My Watchlist

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Articles & Videos

Immutep notches upward on first lung cancer patient dosing

Immutep Ltd has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial in its final stage of clinical study.

25 Mar 2025 11:17 (AEDT)

Immutep dips as safety test for flagship drug IMP761 shows no adverse effects

Immutep has reported a small-scale conceptual safety test among 5 patients using flagship drug IMP761 has seen no adverse effects.

17 Dec 2024 10:27 (AEDT)

Immutep snaffles A$3.6M from French government for R&D

Immutep Ltd has received a R&D award of around A$3.6 million to develop two of its immunotherapy candidates

24 Sep 2024 10:11 (AEST)

Immutep doses first human patient with IMP761 – a possible broad-ranging autoimmune treatment

Immutep (ASX:IMM) has confirmed it's dosed the first human patient with its LAG-3 based autoimmune drug candidate IMP761.

14 Aug 2024 09:22 (AEST)

Immutep reports strong response rate from immunotherapies treating carcinomas

Immutep Ltd has reported a slew of positive results from a trial to assess a combination of immunotherapy cancer drugs.

12 Jul 2024 10:03 (AEST)

Immutep targets $100m for lung cancer drug trial tests

Immutep has launched a capital raise aiming to boost its war chest by $100 million to progress late stage trials for lung cancer sufferers.

03 Jun 2024 10:39 (AEST)

Immutep welcomes constructive feedback from German regulator for phase III lung cancer trial

Immutep (ASX:IMM) has welcomed constructive feedback from a German regulatory authority for its planned TACTI-004 phase III trial of efti for first-line treatment of metastatic NSCLC

21 Dec 2023 15:12 (AEDT)

Immutep reports new biomarker data from TACTI-002 phase II trial

Immutep (ASX:IMM) has announced new biomarker data from its phase II TACTI-002 trial for patients with previously untreated unresectable or metastatic NSCLC.

03 Nov 2023 11:28 (AEDT)

Immutep's Efti and Keytruda combo shows strong survival benefits in metastatic non-small cell lung cancer

Immutep (ASX:IMM) has revealed its drug Efti, in combination with Keytruda, has generated significant survival benefits for those suffering from metastatic non-small cell lung cancer.

23 Oct 2023 11:30 (AEDT)

Immutep (ASX:IMM) doses first patient in Europe for AIPAC-003 breast cancer trial

Immutep (ASX:IMM) has enrolled and dosed its first patient at a clinical site in Europe for its integrated Phase II/III AIPAC-003 trial.

25 May 2023 10:31 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
23.5¢ 		Change
-0.010(4.08%) 		Mkt cap ! $344.9M
Open High Low Value Volume
24.0¢ 24.3¢ 23.5¢ $408.8K 1.709M

Buyers (Bids)

No. Vol. Price($)
14 1472949 23.5¢
 

Sellers (Offers)

Price($) Vol. No.
24.0¢ 142000 3
View Market Depth
Last trade - 16.10pm 05/09/2025 (20 minute delay) ?
Last
23.5¢ 		  Change
-0.010 ( 4.08 %)
Open High Low Volume
24.0¢ 24.3¢ 23.5¢ 668944
Last updated 15.55pm 05/09/2025 ?
IMM (ASX) Chart

Top Stories

ASX Market Open: Google, Apple anti-trust win fires Wall Street tech higher, everyone else follows | Sep 4

A calm is settling in late-on in Week 36, with a Google, Apple anti-trust ruling swelling Wall Street and sending the Nasdaq composite ticking up; a green wave that Australian shares seem happy to catch through to Thursday open.Listen to the HotCopper podcast for in-depth discussions and insights...
Lithium Universe, now looking at silver extraction from solar panels, boasts 95% recovery Lithium Universe (ASX:LU7) has reported hitting silver recovery metrics of over 95% from discarded solar panels in a tech validation trial alongside Macquarie Uni focusing on Jet Electrochemical Silver Extraction (JESE) @ with the lion’s share recovered in as little as 7 minutes o...
Trigg Minerals has revealed strong historical drilling results at its Tennessee Mountain Project, confirming high-grade tungsten mineralization HotCopper@s latest Watchlist sees it joined by Trigg Minerals’ (ASX:TMG) Chief Geologist Jonathan King to discuss the company’s recent success with tungsten exploration on-site its US digs. The United States currently doesn’t have a domestic capacit...
Lotus Res sinks -16% to match 19cps raising price; shareholder reaction mixed Lotus Resources (ASX:LOT) has fallen -16% in Thursday trades after raising A$65M in a placement to recommence uranium mining activites in Mali and works on a separate project in Botswana. As ever, raising has prompted mixed reactions on the HotCopper forums, separating the true believers from the...
Listen: HotCopper Wire Podcast 023 – Glowing gold, shining silver, and... wheat collusion? In this HotCopper Wire episode, we look at surging gold and silver as well as Trump's appeals court clash, and a wheat futures conspiracy.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.